Peptilogics’ AI Peptide Platform Could Help Address Orthopedic Unmet Need

Emerging Company Profile: US firm Peptilogics is advancing through the clinic with its lead orthopedic anti-infective drug candidate based on an AI platform that utilizes algorithms to improve peptide design.  

Hip bones with metal, representing joint replacement
PJIs Are Severe Complications That Occur In Patients After Joint Replacement • Source: Shutterstock

Peptilogics, Inc. is planning a 2026 US filing of its lead asset in an orphan orthopedic indication as it works to validate its AI platform that can design peptides with enhanced risk-benefit profiles regardless of drug target or class.

CEO Jonathan Steckbeck told Scrip his rationale for founding the Pittsburgh, PA-based firm in 2013 was two-fold. “The first reason...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Emerging Company Profiles

More from Start-Ups & SMEs